The Technical Analyst
Fate Therapeutics Inc [FATE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Fate Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-4.36% $5.04
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 500.16 mill |
| EPS: | -1.640 |
| P/E: | -3.07 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 99.24 mill |
| Avg Daily Volume: | 2.82 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.07 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.52x |
| Company: PE -3.07 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.40 - 5.68 ( +/- 12.72%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-21 | Redmile Group, Llc | Buy | 3 636 364 | Pre-Funded Warrants to Purchase Common Stock |
| 2024-03-04 | Dulac Edward J Iii | Sell | 2 447 | Common Stock |
| 2024-02-01 | Wolchko J Scott | Buy | 500 000 | Stock Option (Right to Buy) |
| 2024-02-01 | Tahl Cindy | Buy | 425 000 | Stock Option (Right to Buy) |
| 2024-02-01 | Dulac Edward J Iii | Buy | 425 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 40.48 |
| Last 99 transactions |
| Buy: 17 254 718 | Sell: 8 388 589 |
Forecast:
16:00 - $5.04
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.04
Forecast 2: 16:00 - $5.04
Forecast 3: 16:00 - $5.04
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.04 (-4.36% ) |
| Volume | 2.33 mill |
| Avg. Vol. | 2.82 mill |
| % of Avg. Vol | 82.71 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FATE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $6.07 | N/A | Active |
|---|
FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-02 16:01:00 - Press Release
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
San diego, april 02, 2024 (globe newswire) -- fate therapeutics, inc. (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (ipsc)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on april 1, 2024 the company granted restricted stock units (rsus) representing 6,400 shares of its common stock to one newly-hired non-executive employee. the grant was approved by the compensation committee of the company's board of directors and granted under the company's amended and restated inducement equity plan as an inducement material to the new employees entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4)...
2024-03-19 08:44:00 - Press Release
Fate Therapeutics Announces Pricing Of $100 Million Underwritten Offering And Concurrent Private Placement
San diego, march 19, 2024 (globe newswire) -- fate therapeutics, inc. (the “company” or “fate therapeutics”) (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (ipsc)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. the offering includes participation from new and existing institutional investors, including adage capital partners lp., boxer capital, deep track capital, orbimed, suvretta capital and a life-sciences focused investor.
2024-03-05 16:01:00 - Press Release
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
San diego, march 05, 2024 (globe newswire) -- fate therapeutics, inc. (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (ipsc)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the company's common stock at an exercise price per share of $7.74, which was the closing price per share of the company's common stock as reported by nasdaq on the grant effective date of march 1, 2024. the option was approved by the compensation committee of the company's board of directors and granted under the company's amended and restated inducement equity plan as an inducement material to the new employees entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4)...
2024-03-01 08:00:00 - Press Release
Fate Therapeutics To Present At Upcoming March Investor Conferences
San diego, march 01, 2024 (globe newswire) -- fate therapeutics, inc. (the “company” or “fate therapeutics”) (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (ipsc)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the company will participate in the following upcoming investor conferences:
2024-02-26 16:01:00 - Press Release
Fate Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Business Updates
Cirm grant awarded to support phase 1 autoimmunity study of ft819 cd19-targeted car t-cell program for systemic lupus erythematosus; study start-up ongoing at multiple clinical sites
Latest News
2024-04-06 03:21:07 - Zacks Investment Research
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
2024-03-01 08:00:00 - GlobeNewsWire
Fate Therapeutics to Present at Upcoming March Investor Conferences
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
2024-02-27 10:20:24 - Zacks Investment Research
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
2024-02-26 20:25:04 - Seeking Alpha
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript
2024-02-26 18:11:05 - Zacks Investment Research
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.58 per share a year ago.
2024-02-19 11:05:34 - Zacks Investment Research
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-15 08:00:00 - GlobeNewsWire
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update.
2024-01-30 08:56:06 - Zacks Investment Research
Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?
Fate Therapeutics (FATE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2024-01-29 14:53:56 - InvestorPlace
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock
When billionaire investors step into a particular smaller-cap under-the-radar name, investors take notice. That appears to be the case with Fate Therapeutics (NASDAQ: FATE ) today.
2023-12-22 13:32:16 - Zacks Investment Research
Fate Therapeutics (FATE) Upgraded to Buy: Here's Why
Fate Therapeutics (FATE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).